|
1）Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med. 1955; 45: 3-17
|
|
|
|
2）Choi M, Scholl UI, Yue P, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science. 2011; 331: 768-72
|
|
|
|
|
3）Zennaro MC, Jeunemaitre X, Boulkroun S. Integrating genetics and genomics in primary aldosteronism. Hypertension. 2012; 60: 580-8
|
|
|
|
|
|
4）Al-Salameh A, Cohen R, Desailloid R. Overview of the genetic determinants of primary aldosteronism. Appl Clin Genet. 2014; 7: 67-79
|
|
|
|
|
|
5）Monticone S, Hattangady NG, Nishimoto K, et al. Effect of KCNJ5 mutations on gene expression in aldosterone-producing adenomas and adrenocortical cells. J Clin Endocrinol Metab. 2012; 97: 1567-72
|
|
|
|
|
|
6）Williams TA, Monticone S, Crudo V, et al. Visinin-like 1 is upregulated in aldosterone-producing adenomas with KCNJ5 mutations and protects from calcium-induced apoptosis. Hypertension. 2012; 59: 833-9
|
|
|
|
|
|
7）Boulkroun S, Beuschlein F, Rossi GP, et al. Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism. Hypertension. 2012; 59: 592-8
|
|
|
|
|
|
8）Stowasser M. Primary aldosteronism and potassium channel mutations. Curr Opin Endocrinol Diabetes Obes. 2013; 20: 170-9
|
|
|
|
|
|
9）Taguchi R, Yamada M, Nakajima Y, et al. Expression and mutations of KCNJ5 mRNA in Japanese patients with aldosterone-producing adenomas. J Clin Endocrinol Metab. 2012; 97: 1311-9
|
|
|
|
|
|
10）Felizola SJ, Nakamura Y, Satoh F, et al. Glutamate receptors and the regulation of steroidogenesis in the human adrenal gland: the metabotropic pathway. Mol Cell Endocrinol. 2014; 382: 170-7
|
|
|
|
|
|
11）Felizola SJ, Nakamura Y, Arata Y, et al. Metallothionein-3 (MT-3) in the human adrenal cortex and its disorders. Endocr Pathol. 2014; 25: 229-35
|
|
|
|
|
|
12）Nakamura Y, Hattangady NG, Ye P, et al. Aberrant gonadotropin-releasing hormone receptor (GnRHR) expression and its regulation of CYP11B2 expression and aldosterone production in adrenal aldosterone-producing adenoma (APA). Mol Cell Endocrinol. 2014; 384: 102-8
|
|
|
|
|
|
13）Felizola SJ, Nakamura Y, Ono Y, et al. PCP4: a regulator of aldosterone synthesis in human adrenocortical tissues. J Mol Endocrinol. 2014; 52: 159-67
|
|
|
|
|
|
14）Curnow KM, Tusie-Lunaf MT, Pascoe L, et al. The product of the CYP11B2 gene is required for aldosterone biosynthesis in the human adrenal cortex. Mol Endocr. 1991; 5: 1513-22
|
|
|
|
|
|
15）Gomez-Sanchez CE, Qi X, Velarde-Miranda C, et al. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol. 2013; 383: 111-7
|
|
|
|
|
|
16）Nakamura Y, Maekawa T, Felizola SJ, et al. Adrenal CYP11B1/2 expression in primary aldosteronism: Immunohistochemical analysis using novel monoclonal antibodies. Mol Cell Endocrinol. 2014; 392: 73-9
|
|
|
|
|
|
17）Ono Y, Nakamura Y, Maekawa T, et al. Different expression of 11β-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas. Hypertension. 2014; 64: 438-44
|
|
|
|
|
|
18）Doi M, Takahashi Y, Komatsu R, et al. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med. 2010; 16: 67-74
|
|
|
|
|
|
19）Doi M, Satoh F, Maekawa T, et al. Isoform-specific monoclonal antibodies against 3β-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism. J Clin Endocrinol Metab. 2014; 99: 257-62
|
|
|
|
|